LitAlert ~~ GeneLit.com

    • Clinical Utility of Next-Generation Sequencing-Based Panel Testing under the Universal Health-Care System in Japan: A Retrospective Analysis at a Single University Hospital.
    • Inagaki C, Maeda D, Hatake K, Sato Y, Hashimoto K, Sakai D, Yachida S, Nonomura I, Satoh T.
    • Cancers (Basel). 2021 Mar 5;13(5):E1121. doi: 10.3390/cancers13051121.
    • UK's NICE Does Not Recommend Lynparza for BRCA-Mutated Prostate Cancer.
    • [No author given]
    • GenomeWeb. Business & Policy. Regulatory News. 2021 Mar 5.
    • An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer.
    • Stringer-Reasor EM, May JE, Olariu E, Caterinicchia V, Li Y, Chen D, Della Manna DL, Rocque GB, Vaklavas C, Falkson CI, Nabell LM, Acosta EP, Forero-Torres A, Yang ES.
    • Breast Cancer Res. 2021 Mar 4;23(1):30. doi: 10.1186/s13058-021-01408-9.
    • WNT inhibition creates a BRCA-like state in Wnt-addicted cancer.
    • Kaur A, Lim JYS, Sepramaniam S, Patnaik S, Harmston N, Lee MA, Petretto E, Virshup DM, Madan B.
    • EMBO Mol Med. 2021 Mar 4:e13349. doi: 10.15252/emmm.202013349. Epub ahead of print.
    • Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.
    • Javle M, Shacham-Shmueli E, Xiao L, Varadhachary G, Halpern N, Fogelman D, Boursi B, Uruba S, Margalit O, Wolff RA, Golan T.
    • JAMA Oncol. 2021 Mar 4. doi: 10.1001/jamaoncol.2021.0006. Epub ahead of print.
    • Genomic mutation profiling using liquid biopsy in Korean patients with prostate cancer: Circulating tumor DNA mutation predicts the development of castration resistance.
    • Yu J, Cho E, Choi J, Lim JE, Lee J, Kang M, Sung HH, Jeong BC, Seo SI, Jeon SS, Lee HM, Jeon HG.
    • Investig Clin Urol. 2021 Mar;62(2):224-232. doi: 10.4111/icu.20200406.
    • Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer.
    • Okamoto A, Kondo E, Nakamura T, Yanagida S, Hamanishi J, Harano K, Hasegawa K, Hirasawa T, Hori K, Komiyama S, Matsuura M, Nakai H, Nakamura H, Sakata J, Tabata T, Takehara K, Takekuma M, Yokoyama Y, Kase Y, Sumino S, Soeda J, Suri A, Aoki D, Sugiyama T.
    • J Gynecol Oncol. 2021 Mar;32(2):e16. doi: 10.3802/jgo.2021.32.e16. Epub 2020 Dec 10.
    • Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer.
    • Takehara K, Matsumoto T, Hamanishi J, Hasegawa K, Matsuura M, Miura K, Nagao S, Nakai H, Tanaka N, Tokunaga H, Ushijima K, Watari H, Yokoyama Y, Kase Y, Sumino S, Suri A, Itamochi H, Takeshima N.
    • J Gynecol Oncol. 2021 Mar;32(2):e21. doi: 10.3802/jgo.2021.32.e21. Epub 2021 Jan 6.
    • The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.
    • Tokunaga H, Mikami M, Nagase S, Kobayashi Y, Tabata T, Kaneuchi M, Satoh T, Hirashima Y, Matsumura N, Yokoyama Y, Kawana K, Kyo S, Aoki D, Katabuchi H.
    • J Gynecol Oncol. 2021 Mar;32(2):e49. doi: 10.3802/jgo.2021.32.e49.
    • Germline mutations in RAD51C and RAD51D and hereditary predisposition to ovarian cancer.
    • Jana S, Klára L, Markéta J, Petra K, Michal V, Lenka F, Michal Z, Zdenek K.
    • Klin Onkol. 2021 Winter;34(1):26-32. English. doi: 10.48095/ccko202126.